Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130823 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL9595033 | 0.82 | NPC1 (0.49) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL9131206 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL18608415 | 0.80 | MAPT (0.56) | SMN1; SMN2NPC1RAB9AGAAHTT | |
| SCHEMBL18608342 | 0.79 | GBA1 (0.48) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL18608410 | 0.77 | NR4A1 (0.56) | SMN1; SMN2NPC1HPGDRAB9AHTT | |
| SCHEMBL18608548 | 0.76 | NPC1 (0.48) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL18608559 | 0.76 | NPC1 (0.53) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL18608343 | 0.76 | NR3C1 (0.50) | SMN1; SMN2NPC1HPGDRAB9AGAA | |
| SCHEMBL9128642 | 0.75 | HPGD (0.44) | SMN1; SMN2NPC1HPGDRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | disclosed |
| WO-2017040879-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | PARK7, GAA, TYMP | SMN1; SMN2 51/4885NPC1 1208/4885HPGD 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.